1
项与 SpFN_1B-06-PL adjuvanted with QS21(WRAIR) 相关的临床试验A PHASE 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of SARS-COV-2-Spike-Ferritin-Nanoparticle (SPFN_1B-06-PL) Vaccine With Army Liposomal Formulation QS21 (ALFQ) for Prevention of COVID-19 in Healthy Adults.
The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the SpFN COVID-19 vaccine with Army Liposomal Formulation QS21 (ALFQ) adjuvant in healthy adults ages 18-55.
100 项与 SpFN_1B-06-PL adjuvanted with QS21(WRAIR) 相关的临床结果
100 项与 SpFN_1B-06-PL adjuvanted with QS21(WRAIR) 相关的转化医学
100 项与 SpFN_1B-06-PL adjuvanted with QS21(WRAIR) 相关的专利(医药)
100 项与 SpFN_1B-06-PL adjuvanted with QS21(WRAIR) 相关的药物交易